Literature DB >> 11350549

Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis.

A Das1, R K Dhiman, V A Saraswat, M Verma, S R Naik.   

Abstract

BACKGROUND AND AIMS: The natural history of subclinical hepatic encephalopathy (SHE) is unknown. The present study was conducted to study the prevalence and the natural history of SHE in patients with cirrhosis of the liver.
METHODS: One hundred and sixty-five patients with cirrhosis of the liver were studied. A total of nine psychometric tests (trail making and Wechsler adult intelligence scale-performance (WAIS-P) tests) were administered. Subclinical hepatic encephalopathy was present if two or more psychometric tests were abnormal. Seventy-two patients (SHE 40, without SHE 32) also underwent serial psychometric testing on follow-up visits at 6-8 week intervals.
RESULTS: Subclinical hepatic encephalopathy was present in 103 (62.4%) patients. The number and figure connection, block design and picture completion tests were the most useful in the detection of SHE. Severity of SHE, as assessed by the number of abnormal tests, was greater in patients with more severe liver disease. During follow up, SHE tended to persist or worsen in patients with poorer liver function. Although other clinical complications were similar in different groups, overt hepatic encephalopathy developed more commonly in those patients who had SHE at entry compared to those who did not (22.6 vs 5.6%, P = 0.044). Among the patients with SHE, the development of overt hepatic encephalopathy was more common in patients with Child's score of > 6 than with Child's score of <or= 6 (40 vs 5%, P = 0.019).
CONCLUSIONS: We conclude that SHE is common in cirrhosis. The natural history of SHE is worse in patients with advanced cirrhosis and SHE probably predisposes the cirrhotic patient to overt hepatic encephalopathy.

Entities:  

Mesh:

Year:  2001        PMID: 11350549     DOI: 10.1046/j.1440-1746.2001.02487.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  80 in total

1.  Canadian regulations and legal ramifications for hepatic encephalopathy: a descriptive analysis.

Authors:  Henry H Nguyen; Mark G Swain; Philip Wong; Stephen E Congly
Journal:  CMAJ Open       Date:  2018-12-03

2.  Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy.

Authors:  Vicente Felipo; Amparo Urios; Encarna Montesinos; Inmaculada Molina; Maria L Garcia-Torres; Miguel Civera; Juan A Del Olmo; Joaquin Ortega; Jose Martinez-Valls; Miguel A Serra; Norberto Cassinello; Abdallah Wassel; Esperanza Jordá; Carmina Montoliu
Journal:  Metab Brain Dis       Date:  2011-11-10       Impact factor: 3.584

3.  The Treatment of Patients With Hepatic Encephalopathy: Review of the Latest Data from EASL 2010.

Authors:  Kevin D Mullen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-07

4.  Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver.

Authors:  Radha K Dhiman; Roshan Kurmi; Kiran K Thumburu; Sunil H Venkataramarao; Ritesh Agarwal; Ajay Duseja; Yogesh Chawla
Journal:  Dig Dis Sci       Date:  2010-05-28       Impact factor: 3.199

Review 5.  Characteristics of minimal hepatic encephalopathy.

Authors:  Piero Amodio; Sara Montagnese; Angelo Gatta; Marsha Y Morgan
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

Review 6.  Contribution of altered signal transduction associated to glutamate receptors in brain to the neurological alterations of hepatic encephalopathy.

Authors:  Vicente Felipo
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

Review 7.  Minimal hepatic encephalopathy.

Authors:  Laura M Stinton; Saumya Jayakumar
Journal:  Can J Gastroenterol       Date:  2013-10       Impact factor: 3.522

8.  Memory impairment in patients with cirrhosis.

Authors:  Funda Bahceci; Bulent Yildirim; Melih Karincaoglu; Ibrahim Dogan; Birsen Sipahi
Journal:  J Natl Med Assoc       Date:  2005-02       Impact factor: 1.798

9.  Pannexin1 as a novel cerebral target in pathogenesis of hepatic encephalopathy.

Authors:  Papia Mondal; Surendra Kumar Trigun
Journal:  Metab Brain Dis       Date:  2014-05-08       Impact factor: 3.584

10.  Driving Performance Among Patients with Cirrhosis Who Drove to Their Outpatient Hepatology Clinic Appointments.

Authors:  Paul J Thuluvath; Anantha Nuthalapati; Jennifer Price; Anurag Maheshwari
Journal:  J Clin Exp Hepatol       Date:  2015-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.